Siagran Drug Interactions

Because of presystemic clearance of Sumatriptan via MAO-A so that the use of MAO-A inhibitors with Sumatriptan may decrease Sumatriptan clearance and increase half-life and blood concentrations of Sumatriptan. Moreover patients receiving Sumatriptan should be cautioned about risk of serotonin syndrome when concomitant use of MAO-A inhibitors (e.g. moclobemide). Concurrent use of Sumatriptan and MAO-A inhibitors or use of Sumatriptan within 2 weeks of discontinuance of MAO-A inhibitor therapy is contraindicated.
Because ergot alkaloids have been reported to cause prolonged vasospastic reactions and the vasoconstrictor effects of these drugs may be additive to those of Sumatriptan. The use of Sumatriptan within 24 hours of treatment with an ergot-containing medication is contraindicated.
Concurrent use Sumatriptan with selective serotonin-reuptake inhibitors (SSRI: e.g. fluoxetine, fluvoxamine, paroxetine, sertraline) or norepinephrine-reuptake inhibitors (SNRIs: e.g. duloxetine) can cause serotonin syndrome. If use concurrently 5-HT₁ receptor agonists with SSRIs or SNRIs.
The risk of vasospastic reactions may be increased. Coadministration of two 5-HT₁ agonist within 24 hours of each other is contraindicated.